Please upgrade your browser.
Portland-area researchers harness immune system to shrink tumors
A boy with a rare type of cancer who had his health insurance plan canceled after the Affordable Care Act took effect...
A potential mimic of multilocular cystic renal cell carcinoma
Nephroprotective role of ascorbic acid
Tubulocystic Carcinoma of the Kidney
Is there an association between blood type and prognosis?
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment. Because HD IL-2-associated toxicity is severe, it would be beneficial for clinicians to determine if a patient would respond favorably to this treatment prior to side effect onset.
OBJECTIVE: To investigate the prognosis and prognostic factors of patients with metastatic renal cell carcinoma who underwent metastasectomy.
Presentations from the 12 International Kidney Cancer Symposium, held in October 2013, at Chicago, Illinois, USA.
|NeonCRM by Neon One|